{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:29:29Z","timestamp":1790285369815,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.euf.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T19:26:40Z","timestamp":1544729200000},"page":"10-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Antibiotics in the Treatment of Urinary Tract Infections"],"prefix":"10.1016","volume":"5","author":[{"given":"Kurt G.","family":"Naber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M.E.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.11.012_bib0005","series-title":"EAU guidelines on urological infections","author":"Bonkat","year":"2017"},{"key":"10.1016\/j.euf.2018.11.012_bib0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000486138","article-title":"The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention","volume":"100","author":"Kranz","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2018.11.012_bib0015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.11.012_bib0020","first-page":"791","article-title":"Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study","volume":"32","author":"Tandogdu","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.11.012_bib0025","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2018.11.012_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.euf.2018.11.012_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/21505594.2016.1207834","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"8","author":"Thaden","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.euf.2018.11.012_bib0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euf.2018.11.012_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.euf.2018.11.012_bib0050","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1093\/ofid\/ofx163.1396","article-title":"Meropenem-vaborbactam vs. piperacillin-tazobactam in TANGO I (a Phase 3 randomized, double-blind trial): outcomes by baseline MIC in adults with complicated urinary tract infections or acute pyelonephritis. Poster, IDSA 2017","volume":"4","author":"Walsh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.euf.2018.11.012_bib0055","series-title":"FDA approves new antibacterial drug","author":"U.S. Food & Drug Administration","year":"2017"},{"key":"10.1016\/j.euf.2018.11.012_bib0060","series-title":"TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE","author":"The Medicines Company","year":"2017"},{"key":"10.1016\/j.euf.2018.11.012_bib0065","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.euf.2018.11.012_bib0070","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.euf.2018.11.012_bib0075","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.euf.2018.11.012_bib0080","series-title":"Positive top-line results for cefiderocol pivotal cUTI clinical trial","author":"Shionogi","year":"2017"},{"key":"10.1016\/j.euf.2018.11.012_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.euf.2018.11.012_bib0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.euf.2018.11.012_bib0095","series-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) (Poster L2-2118a)","author":"Riddle","year":"2012"},{"key":"10.1016\/j.euf.2018.11.012_bib0100","series-title":"27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results of the EPIC study. Poster 1855","author":"Cloutier","year":"2017"},{"issue":"April (4)","key":"10.1016\/j.euf.2018.11.012_bib0105","article-title":"Efficacy and safety of finafloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: an explorative randomized phase II clinical study","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicr Agents Chemother"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:48:17Z","timestamp":1762498097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918303730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2405456918303730"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.11.012","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Antibiotics in the Treatment of Urinary Tract Infections","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}